Dr. Reddy's Laboratories Ltd Common Stock (RDY)
Stock · NYSE · Health Care
$12.18as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Resistance level
$13.09
Industry
Biotechnology: Pharmaceutical Preparations
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 27,527
- Website
- www.drreddys.com
Fundamentals
- 1-day range
- $12.22$12.39
- Market cap
- $10.11B
- P/E (trailing)
- 29.21
- P/E (forward)
- 18.90
- EPS (trailing)
- $0.42
- Dividend yield
- 0.68%
- Beta
- 0.24
- Avg. volume
- 2.52M
- Ex-dividend date
- July 9, 2026
- Dividend pay date
- August 5, 2026
52-week range
$11.36$15.67
Next earnings: October 22, 2026confirmed
Forecasts
5 analyst ratings
Buy 40%
Hold 40%
Sell 20%
1-year price forecast
High
$15.77
+29.5%
Median
$13.09
+7.5%
Low
$11.39
-6.5%
Dr. Reddy's Laboratories Ltd Common Stock Competitors
Chosen by industry and closest market cap.
- RDYDr. Reddy's Laboratories Ltd Common Stock$12.18▲ 0.16%Market cap $10.11BP/E 29.21$11.36$15.67
- CYTKCytokinetics Incorporated Common Stock$72.17▼ 7.36%Market cap $10.13BP/E —$35.22$88.31
- PRAXPraxis Precision Medicines Inc. Common Stock$344.95▼ 6.23%Market cap $10.32BP/E —
- SMMTSummit Therapeutics Inc. Common Stock$13.71▼ 4.33%Market cap $10.80BP/E —$12.07$29.23
- AXSMAxsome Therapeutics Inc. Common Stock$199.01▼ 3.52%Market cap $10.81BP/E —$112.9$260.19
- PTGXProtagonist Therapeutics Inc. Common Stock$144.15▼ 3.58%Market cap $9.40BP/E —
- SYRESpyre Therapeutics Inc. Common Stock$90.4▼ 3.43%Market cap $9.12BP/E —$14.51$110.18
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Ltd Common Stock | $10.11B | 29.21 | $12.18 | ▲ 0.16% | $11.36$15.67 |
| CYTK Cytokinetics Incorporated Common Stock | $10.13B | — | $72.17 | ▼ 7.36% | $35.22$88.31 |
| PRAX Praxis Precision Medicines Inc. Common Stock | $10.32B | — | $344.95 | ▼ 6.23% | |
| SMMT Summit Therapeutics Inc. Common Stock | $10.80B | — | $13.71 | ▼ 4.33% | $12.07$29.23 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.81B | — | $199.01 | ▼ 3.52% | $112.9$260.19 |
| PTGX Protagonist Therapeutics Inc. Common Stock | $9.40B | — | $144.15 | ▼ 3.58% | |
| SYRE Spyre Therapeutics Inc. Common Stock | $9.12B | — | $90.4 | ▼ 3.43% | $14.51$110.18 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement TerminationBenzinga · 8/7/2026
- Dr. Reddy's Laboratories Limited - Depositary Receipt (RDY) Price Target Decreased by 12.65% to 12.93Fintel · 8/4/2026
- Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month RunSeekingAlpha · 7/31/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 114.13M
- Total value held
- $1.52B
- Institutional holders
- 241
Top holders this quarter
- Unknown17.18M
- Unknown11.59M
- Unknown9.98M
- Unknown9.37M
- Unknown8.00M
- Unknown7.86M
- Unknown5.32M
- Unknown4.03M
- Unknown3.18M
- Unknown3.10M
See the full, filterable feed with live charts on the MarketWall dashboard.